Urology Times SUO internship program member William Parker, MD, discusses a retrospective review of more than 100 patients at Columbia University Medical Center in New York.
Urology Times SUO internship program member Katie Murray, DO, reports on a study evaluating the differences in urine cytology and UroVysion FISH testing results among clinically meaningful patient subgroups.
Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.
A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
Work-related risks for bladder cancer are on the rise, but the occupations putting workers at risk seem to be evolving, according to a meta-analysis published online in JAMA Oncology (Oct. 8, 2015).
Researchers have recently made progress in understanding a fundamental signaling cascade, the Programmed Death 1 (PD-1) receptor-ligand pathway,1 which holds long-awaited promise in bladder cancer intervention.
In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.
A new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.
Urology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas—an information-packed, condensed summary of the top papers and presentations.